Katsuhisa Kawanami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Katsuhisa Kawanami has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Masataka Deie
Department of Orthopedic Surgery, Aichi Medical University, Nagakute, Aichi, Japan
3 shared publications - Toshihiro Matsuo
Department of Orthopedic Surgery, Aichi Medical University, Nagakute, Aichi, Japan
3 shared publications - Akihito Nagano
Department of Orthopaedic Surgery, Gifu University Graduate School of Medicine, Gifu 501-1194, Japan
2 shared publications - Atsuhiko Hirasawa
Department of Orthopedic Surgery, Aichi Medical University, Nagakute, Aichi, Japan
2 shared publications - Eiji Kozawa
Department of Orthopaedic Surgery, Nagoya Memorial Hospital, Nagoya 468-8520, Japan
2 shared publications - Emiko Takahashi
Department of Surgical Pathology, Aichi Medical University Hospital, Nagakute, Japan
2 shared publications
Latest Publications
- Open Access
Clinical Outcome in Elderly Patients (Aged ≥ 65 Years) Treated with Chemotherapy for Advanced Soft Tissue Sarcomas: A Tokai Musculoskeletal Oncology Consortium Study
Background/Objectives: Chemotherapy is recommended for patients with advanced soft tissue sarcoma (STS). However, chemotherapy is less aggressive in elderly patients than in younger patients owing to comorbidities and other health problems. This multicenter study aimed to examine the outcomes of elderly patients treated with chemotherapy for advanced STS. Methods: The study cohort included 60 men and 71 women with a mean age of 73 years. The mean follow-up duration was 22.9 months. Results: As first-line treatment, the doxorubicin-containing regimen was the most frequently used. Dose reduction was more frequent in patients aged ≥ 75 years than in those aged ≤ 74 years. Complete response occurred in two patients and partial response in eight patients. The objective response rate was 8.2%. The 1- and 2-year survival rates after first-line chemotherapy were 61.8% and 40.2%, respectively. The median survival time was 19 months. In multivariate analysis, patients with performance status (PS) 2 or 3 had poorer survival than those with PS 0 or 1. The median survival times for patients with PS 0 or 1 and PS 2 or 3 were 22.1 and 4.3 months, respectively. Among 131 patients, no fatal adverse events occurred, although chemotherapy was discontinued due to adverse events in 28 patients. Conclusions: Chemotherapy for advanced STS in elderly patients may be effective in those with good PS, although it should be considered to evaluate the benefits and risks of cytotoxic chemotherapy.
Open AccessClinical Outcome in Elderly Patients (Aged ≥ 65 Years) Treated with Chemotherapy for Advanced Soft Tissue Sarcomas: A Tokai Musculoskeletal Oncology Consortium Study
Background/Objectives: Chemotherapy is recommended for patients with advanced soft tissue sarcoma (STS). However, chemotherapy is less aggressive in elderly patients than in younger patients owing to comorbidities and other health problems. This multicenter study aimed to examine the outcomes of elderly patients treated with chemotherapy for advanced STS. Methods: The study cohort included 60 men and 71 women with a mean age of 73 years. The mean follow-up duration was 22.9 months. Results: As first-line treatment, the doxorubicin-containing regimen was the most frequently used. Dose reduction was more frequent in patients aged ≥ 75 years than in those aged ≤ 74 years. Complete response occurred in two patients and partial response in eight patients. The objective response rate was 8.2%. The 1- and 2-year survival rates after first-line chemotherapy were 61.8% and 40.2%, respectively. The median survival time was 19 months. In multivariate analysis, patients with performance status (PS) 2 or 3 had poorer survival than those with PS 0 or 1. The median survival times for patients with PS 0 or 1 and PS 2 or 3 were 22.1 and 4.3 months, respectively. Among 131 patients, no fatal adverse events occurred, although chemotherapy was discontinued due to adverse events in 28 patients. Conclusions: Chemotherapy for advanced STS in elderly patients may be effective in those with good PS, although it should be considered to evaluate the benefits and risks of cytotoxic chemotherapy.
- Open Access
- 6 July 2021
- Published by MDPI AG in Preprints.org
Effect of Neoadjuvant Therapies on Soft Tissue Sarcomas with Tail-Like Lesions: A Multicenter Retrospective Study
Several types of soft tissue sarcomas have peripheral infiltrative growth characteristics called tail-like lesions. The efficacy of neoadjuvant therapy for tumors with tail-like lesions has not been elucidated. From 2012 to 2019, we analyzed 36 patients with soft tissue sarcoma with tail-like lesions treated with neoadjuvant therapy, including chemotherapy, radiotherapy, or both. The ef-fect of neoadjuvant therapy on the tail sign was investigated by analyzing the change in tail-like lesions during neoadjuvant therapy and histological responses. The median length of the tail-like lesion reduced from 29.5 mm at initiation to 19.5 mm after neoadjuvant therapy. The extent of shrinkage in tail-like lesion was related to the histopathological responses in the main part. Com-plete disappearance of the tail-like lesion was observed in 12 patients; however, it was not related to achieving a microscopically negative margin. The oncologic outcomes did not significantly differ between cases with complete disappearance of tail-like lesions or not. This study indicated the shrinkage of tail-like lesions did not have significant effect on complete resection or improve-ment of clinical outcomes. A more comprehensive evaluation is needed to elaborate on the surgi-cal strategy.
- 6 July 2021
- Published by MDPI AG in Preprints.org
Open AccessEffect of Neoadjuvant Therapies on Soft Tissue Sarcomas with Tail-Like Lesions: A Multicenter Retrospective Study
Several types of soft tissue sarcomas have peripheral infiltrative growth characteristics called tail-like lesions. The efficacy of neoadjuvant therapy for tumors with tail-like lesions has not been elucidated. From 2012 to 2019, we analyzed 36 patients with soft tissue sarcoma with tail-like lesions treated with neoadjuvant therapy, including chemotherapy, radiotherapy, or both. The ef-fect of neoadjuvant therapy on the tail sign was investigated by analyzing the change in tail-like lesions during neoadjuvant therapy and histological responses. The median length of the tail-like lesion reduced from 29.5 mm at initiation to 19.5 mm after neoadjuvant therapy. The extent of shrinkage in tail-like lesion was related to the histopathological responses in the main part. Com-plete disappearance of the tail-like lesion was observed in 12 patients; however, it was not related to achieving a microscopically negative margin. The oncologic outcomes did not significantly differ between cases with complete disappearance of tail-like lesions or not. This study indicated the shrinkage of tail-like lesions did not have significant effect on complete resection or improve-ment of clinical outcomes. A more comprehensive evaluation is needed to elaborate on the surgi-cal strategy.
- 5 January 2021
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 28 (5) , 1175-1178
Bone metastasis of proximal humerus treated by reverse shoulder arthroplasty with polyester mesh: A case report
- 5 January 2021
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 28 (5) , 1175-1178
Bone metastasis of proximal humerus treated by reverse shoulder arthroplasty with polyester mesh: A case report
- 1 January 2021
- Published by Elsevier in Journal of Orthopaedics
- Vol. 23, 216-218
The effect of denosumab administration on bone metabolism for treatment of spinal metastasis
- 1 January 2021
- Published by Elsevier in Journal of Orthopaedics
- Vol. 23, 216-218
The effect of denosumab administration on bone metabolism for treatment of spinal metastasis
- 1 March 2020
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 25 (2) , 349-353
Two cases of pelvic sarcoma in the acetabulum with >10-year follow-ups after carbon ion radiotherapy
- 1 March 2020
- Published by Elsevier in Journal of Orthopaedic Science
- Vol. 25 (2) , 349-353
Two cases of pelvic sarcoma in the acetabulum with >10-year follow-ups after carbon ion radiotherapy
- 7 May 2018
- Published by Elsevier in Journal of Orthopaedics
- Vol. 15 (2) , 606-609
Bizarre parosteal osteochondromatous proliferation of the femur: A case report
- 7 May 2018
- Published by Elsevier in Journal of Orthopaedics
- Vol. 15 (2) , 606-609
Bizarre parosteal osteochondromatous proliferation of the femur: A case report
- 1 January 2018
- Published by Medknow in Indian Journal of Cancer
- Vol. 55 (2) , 176-178
Clinical outcomes of limb salvage surgery with postoperative intensity-modulated radiation therapy for soft-tissue sarcoma and metastasis
OBJECTIVE: The primary aim of intensity-modulated radiation therapy (IMRT) for treating soft tissue sarcoma of an extremity is the reduction of morbidity and maintenance of local control. METHODS: We evaluated the outcomes and toxicity of adjuvant IMRT following function-preserving surgery to treat patients with soft tissue sarcoma and metastasis of the extremities. We retrospectively reviewed prospective databases at Kure Medical Center and Aichi Medical University between 2013 and 2016 and identified 10 patients with lower extremity soft tissue sarcoma who underwent both limb-sparing surgery and postoperative IMRT at one of our institutions. RESULTS: There were 7 men and 3 women (mean age, 67.2 years; range, 48–87 years) included in the study. Of these, four patients were continuously disease-free, two showed no evidence of disease, and four died due to disease. The average functional score was 82% (range, 53–100%). Among the 10 patients, 2 (22%) had grade 1–2 edema and 1 (11%) had grade 2 joint stiffness. Another patient developed grade 2 acute dermatitis. There were no severe complications such as infection, tissue necrosis, fracture, or nerve palsy. CONCLUSION: Although the number of patients in this study was small, our results show that adjuvant IMRT following function-preserving surgery for soft tissue sarcoma of the extremity can be valuable for treating unmanageable tumors.
- 1 January 2018
- Published by Medknow in Indian Journal of Cancer
- Vol. 55 (2) , 176-178
Clinical outcomes of limb salvage surgery with postoperative intensity-modulated radiation therapy for soft-tissue sarcoma and metastasis
OBJECTIVE: The primary aim of intensity-modulated radiation therapy (IMRT) for treating soft tissue sarcoma of an extremity is the reduction of morbidity and maintenance of local control. METHODS: We evaluated the outcomes and toxicity of adjuvant IMRT following function-preserving surgery to treat patients with soft tissue sarcoma and metastasis of the extremities. We retrospectively reviewed prospective databases at Kure Medical Center and Aichi Medical University between 2013 and 2016 and identified 10 patients with lower extremity soft tissue sarcoma who underwent both limb-sparing surgery and postoperative IMRT at one of our institutions. RESULTS: There were 7 men and 3 women (mean age, 67.2 years; range, 48–87 years) included in the study. Of these, four patients were continuously disease-free, two showed no evidence of disease, and four died due to disease. The average functional score was 82% (range, 53–100%). Among the 10 patients, 2 (22%) had grade 1–2 edema and 1 (11%) had grade 2 joint stiffness. Another patient developed grade 2 acute dermatitis. There were no severe complications such as infection, tissue necrosis, fracture, or nerve palsy. CONCLUSION: Although the number of patients in this study was small, our results show that adjuvant IMRT following function-preserving surgery for soft tissue sarcoma of the extremity can be valuable for treating unmanageable tumors.
- 2 July 2016
- Published by Elsevier in Journal of Orthopaedics
- Vol. 13 (4) , 313-315
An extremely rare case of a glomus tumor in the popliteal fossa
- 2 July 2016
- Published by Elsevier in Journal of Orthopaedics
- Vol. 13 (4) , 313-315
An extremely rare case of a glomus tumor in the popliteal fossa